Irene Tsung is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 44 publications with 273 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstellasProgram year20254 paymentsResearch$209,439openpaymentsdata.cms.gov ↗
- Merck & Co.Program year20252 paymentsResearch$88,114openpaymentsdata.cms.gov ↗
- Ares TradingProgram year20251 paymentResearch$10,320openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.3%Cytochrome P450 17A1 Inhibitor38.1%Abiraterone Acetate100%Part D≥33 patientsAndrogen Receptor Inhibitor8.1%Xtandi75%Bicalutamide25%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
37.7%Corticosteroid34.7%Prednisone100%Part D≥39 patientsSerotonin-3 Receptor Antagonist2.9%Ondansetron Hcl100%Part D<11 patientsNervous system
5.7%Phenothiazine5.7%Prochlorperazine Maleate100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry
European Urology Open Science
2026 - ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.
Journal of Clinical Oncology
2026 - Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer
JCO Precision Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Joshua Ehrlich, MD
University of Michigan
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”